Furthermore, AKT inhibitors like capivasertib are undergoing rigorous investigation for their efficacy against breast cancers with specific genetic aberrations such as PIK3CA mutations or the AKT1E17K mutation. The gene discussed is PIK3CA; the disease is breast cancer.